Axbio released the latest single-molecule gene sequencer and smart biochip

Time: 2019-7-2 11:15:43

On June 28, 2019, Axbio held a new product launch conference themed as “Smartness Leads to Changes” at the Courtyard by Marriott Shenzhen Bay. A number of academicians, investment institutions, industry experts and media from China and Russia's bio-industry attended the conference and witnessed the launch of Axbio's fourth-generation gene sequencer based on the smart biochip platform.


Figure 1: Banner of the product release conference

Figure 2: Opening speech by Dr.Igor Ivanov

Axbio COO, Dr. Igor Ivanov PhD from University of St. Petersburg,Russiaopenedthe session with “It is such a delight to have friends comingfrom afar” in Chinese, and welcomed theguests and explained Axbio’s mission of utilizing smart biochip-based mobilesequencers to serve global healthcare.

Figure 3: Guest speech at the conference,Dr Ji Shishan, Chairman of STRI

Dr Ji Shishan, Chairman of ShenzhenTsinghua Research Institute saidthat Axbio accumulated multiple years of research and developmentefforts by international scientists, and contributed to the human health.Shenzhen Tsinghua Research Institute continuously supports
Axbio’s R&D center at STRI andits transition from RD to applications.

Mr. Luo Fei, Chairman of Green PineGroup

Mr. Chen Yong, Managing Director ofChina Resources Innovation Fund

MrGuyEristoff, CEO of Tower Jazz Panasonic

Figure 4: Conference speech,Mr. Luo Fei (top), Mr. Chen Yong (middle), Mr. Guy Eristoff (below)


Mr. Luo Fei, Chairman of GreenPine Group, said that the field of scientific and technologicalinnovation is the frontier for investment. This project gathers globalscientists to cooperate and promote innovation. Green Pine strongly supportsAxbio. Mr. Chen Yong, Managing Director of China Resources InnovationFund, said that thesuccessful introduction of the latest single-molecule gene sequencer by Axbio willgreatly promote the development of precision medicine. It will continue tosupport and promote Axbio’s products. Mr. Guy Eristoff, CEO ofTowerJazz Panasonic said that the company's rigorous scientificattitude and craftsmanship are bound to lead it to a successful high-techcompany.


Launching Ceremony Guests:

·    Dr. Tian Hui, CEO of AxBio Inc.,

·    Dr. Igor Ivanov, COO of AxBioInc.

·    Dr. Ji Shishan, ShenzhenTsinghua Research Institute,

·    Dr. LiuWeiqiang, Executive Vice Chairman of Shenzhen Tsinghua Research Institute,

·    Dr. Andrey Lisitsa, Academicianof the Russian Academy of Sciences, Director of the Russian Federal Scientificand Research Institute of Biomedical Chemistry;

·    Dr. Alexander Lavrov of RussianResearch Centre of Medical Genetics,

·    Mr. Guy Eristoff, CEO of TowerJazz Panasonic,

·    Mr. Luo Fei, Chairman of Green Pine Group,

·    Mr. Feng Jie, Vice President ofLeaguer Group,

·    Mr. Zhao Mingkai, ExecutiveDirector of China Resources Innovation Fund,

·    Mr. Meng Gang, Partner ofPengrui Group,

·    Dr. Jin Xuecheng, Partner of TsingyuanVenture Capital

·    Mr. Wang Senzi,

·    Dr. Xue Liang, CTO of YanengBio, and

·    Li Jingxiang, ExecutiveDirector of Strategic Investment Center of BGI Group.

Witnessed by representativesand friends from Shenzhen Tsinghua Research Institute, Green Pine Group, LeaguerGroup, China Resources Group, Pengrui Group, and BGI Group, AXP100 genesequencer and smart biochip chip were successfully released.

Figure 6: Dr. Tian Hui,introduces new products

After the launchingceremony, Axbio CEO Dr. Tian Hui gave a detailed introductionto the company's new products. Dr. Tian Hui first introduced the fourth-generation sequencer AXP100, asingle-molecule sequencer that does not require PCR and does not rely onoptical detection, which simplifies the sequencing steps and reduces the costof the instrument. The four-generation sequencer combines the advantagesof second-generation sequencing, 2.5-generation and third-generation techniquesto achieve high-accuracy, long-read, single-molecule real-time sequencingtechnology. The introduction of a new generation of sequencers will drivethe widespread use of clinical to consumer markets to serve human health.

Witnessed by the audience, Dr.Tian Hui and the team revealed the internal structure of the AXP100 sequencer, anddemonstrated the whole process of initialization, self-test, cartridge loading,biochemical reaction and electrical signal output, which aroused great interestfrom the guests.

Figure 7: AXP100 Gene Sequencer (left), Axbio Smart Biochip CMOSwafer (right)

In addition to thefourth-generation sequencer AXP100, Dr. Tian also introduced the smart biochipplatform. In March 2019, Axbio and TowerJazz, a global specialty fableader, developed the Microfluidics Bio-CMOS platform, a smart biochipplatform, for high-throughput sequencing and molecular diagnostics.

The “nail cover”-sized smartbiochip integrates 1 million sensor channels and an active microfluidic systemfor gene sequencing and clinical diagnosis with minimal blood or otherbiological samples. The product can shorten the human genome sequencingfrom the current 1-2 weeks to one day. Comparedto the mainstream sequencers currently on the market, the MicrofluidicsBio-CMOS platform offers significant advantages in terms of cost, speed and throughput.

Figure 8: Signing Ceremony ofthe Strategic Collaboration Agreements

At the product releaseconference, Dr. Tian Hui and Dr. Igor Ivanov signed strategiccollaboration agreements with Russia IBMC Research Institute, Tower JazzPanasonic, Suzhou Institute of Biomedical Engineering of Chinese Academy ofSciences, Xbiome Inc., and Yaneng Bio, respectively.

Subsequently, Dr. AndreyLisitsa, Academician of the Russian Academy of Sciences, and Dr. AlexanderLavrov of the Russian Research Centre of Medical Genetics, gave wonderfulspeeches to share the potential of high-throughput and high-sensitivity smartbiochips in proteomics and long-length, low-cost sequencing technologies for clinicalapplications.


Andrey-Lisitsa (Academicianof the Russian Academy of Sciences), Alexander Lavrov (the Russian ResearchCentre of Medical Genetics), Nikolay Sergeev (CTO of a startup), XueLiang (CTO of Yaneng Bio), Yang Haitao (Chairman ofZhuhai Biocode), LiJingxiang (Executive Director of Strategic Investment Center of BGIGroup).

In the guest roundtable forumunder the theme of "Microfluidic Biochip Development Status andApplication Market Prospects" and "Genetic Sequencing ClinicalApplication Status and Future Development Trends" hosted by Dr. He Yun of Axbio, six industryexperts held exciting discussion around these topics. Dr. Xue Liang, CTO of YanengBio, said that the application of microfluidic chips includes digital PCR andNGS, microbes, etc. The main advantages are reflected in the low dosage ofreagents, automation, high throughput, and full closure to avoid samplecontamination. There are still many applications that can be developed. It isbelieved that the CMOS chip of Axbio will have a very broad application scope.Mr. Li Jingxiang, Executive Director of Strategic Investment Center of BGIGroup, said that sequencing in China is strictly regulated from research anddevelopment to clinical practice, and a large amount of clinical sample dataneeds to be accumulated. If the cost of sequencing can be greatly reduced, itwill definitely lead to broader clinical applications. Dr. Yang Haitao,Chairman of Zhuhai Biocode, mentioned that microfluidics has many clinicalapplication scenarios, and the market for POCT detection kits for differentdiseases is huge. Dr. Lavrov pointed out that long-length long sequencing ismore suitable for the field of CNV and analysis of complex structuralvariations. In addition to clinical applications, the sequencing platform ofAxbio can be applied to environmental, microbial and animal and plant research.

Up to now, Axbio's smartbiochips are world-leading platformand can be widely used in whole genome sequencing, targeted sequencing, RNAsequencing, epigenetics, metagenomics, etc. It can also be applied to thedetection of proteins, microorganisms, and toxic compounds, and greatlyimproves the existing detection throughput. In the future, with the latestAXP100 gene sequencer and smart biochip technology, Axbio will unveil themystery of genetic information and provide a powerful tool for the rapiddevelopment of precision medicine.

About Axbio (安序源)

Founded in 2016, Axbio is aSilicon Valley start-up company. The company is deeply rooted in precisionmedicine and healthcare industry, performing research and development of coretechnologies, manufacturing next-generation gene sequencing and precision diagnosticequipment, and providing complete solutions for the industry. The company hasR&D centers in Silicon Valley and Shenzhen Tsinghua University ResearchInstitute. It is well funded by the leading venture capital groups.

Thecompany’s leadership consists of series entrepreneurs of Silicon Valley, executivesof global corporations, senior engineers and scientists. The team has a wealthof experience in creating, managing, operating, and successfully exitinghigh-tech companies. The team has full coverage over all the disciplines requiredto develop molecular diagnostics and gene sequencing products, includingintegrated circuits, semiconductor, biochemistry, organic chemistry, surfacephysics, microfluidics, physical chemistry, big data, artificial intelligence, andetc.

Contact us

Address: B203,No.19 Gaoxin South 7th Rd., Nanshan Dist., Shenzhen, Guangdong, China
Phone: +86 755 86969487
Mobile: +86 18002564515